| |
|
Form Serial Number: |
DA20210930E00078
|
| 1.
Date of relevant event: |
28/09/2021
(dd/mm/yyyy)
|
| 2.
Date when director became aware of the relevant event/ interest in the shares (if later): |
(dd/mm/yyyy)
|
| 3.
Stock code: |
01477 |
| 4.
Name of listed corporation: |
Ocumension Therapeutics - B |
| 5.
Class of shares: |
Ordinary Shares |
| 6.
Number of issued shares in class: |
639,012,175 |
| 7.
Name of director (English) as printed on HKID Card/Passport: |
| (Surname) |
Liu |
| (Other names) |
Ye |
|
|
|
| 10.
Name of director (Chinese): |
|
| 11.
Chinese Character Code as printed on HKID Card: |
|
| |
| 24.
Details of relevant event: |
|
|
Brief description of relevant event
|
Capacity in which shares were/are held
|
Number of shares bought/sold or involved
|
Currency of transaction |
On Exchange
|
Off Exchange
|
|
Before relevant event
|
After relevant event
|
Highest price (per share)
|
Average price (per share)
|
Average consideration (per share)
|
Consideration code
|
| Long position |
| 1711 | Miscellaneous
Other (you must briefly describe the relevant event in the Supplementary Information box) |
|
|
|
69,633,490 |
|
|
|
|
|
| Short position |
|
|
|
|
|
|
|
|
|
| |
|
| 25.
Total shares in listed corporation immediately before the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 69,633,490 | 10.91 |
|
| |
| 26.
Total shares in listed corporation immediately after the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 69,633,490 | 10.89 |
|
| |
| 27.
Capacity in which interests disclosed in Box 26 are held: |
| Code describing capacity | Number of shares |
| |
| |
|
| |
| 28.
Further information in derivative interests in listed corporation : |
| Derivatives code |
Exercise period (dd/mm/yyyy) |
Consideration - if derivatives granted by listed corporation |
Number of shares |
| | | Begins | Ends | Currency | Price for grant | Currency | Exercise price | Currency | Price on assignment | |
| Long position | | 4108 | Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box) |
| 10/07/2020 | 10/07/2022 | USD | 0 | USD | 0.001 | | | 8,711,100 |
| Long position | | 4108 | Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box) |
| 10/07/2020 | 10/07/2022 | USD | 0 | USD | 0.188 | | | 4,131,140 |
| Long position | | 4108 | Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box) |
| 10/07/2020 | 10/07/2022 | USD | 0 | USD | 0.188 | | | 17,294,470 |
| Long position | | 4108 | Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box) |
| 10/07/2020 | 30/04/2030 | USD | 0 | USD | 0.188 | | | 11,990,050 |
| Long position | | 4108 | Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box) |
| 31/08/2021 | 31/08/2031 | USD | 0 | HKD | 27.430 | | | 8,668,000 |
| Long position | | 4108 | Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box) |
| 31/08/2021 | 31/08/2031 | USD | 0 | USD | 0.000 | | | 13,002,000 |
|
| |
| 29.
Further information in relation to interests of children under 18 and/or spouse: |
| Child/Spouse | Name of child/spouse | Number of shares |
| | |
|
| |
| 30.
Further information in relation to interests of corporations controlled by Director: |
| Name of controlled corporation | Address and place of incorporation | Name of controlling person | % control | Direct interest (Y/N) | Number of shares |
| | | | | |
|
| |
| 31.
Further information in relation to interests held by Director jointly with another person: |
| Name of joint shareholder | Address | Number of shares |
| | |
|
| |
| 32.
Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust: |
| Names of Trust | Address | Status code | Number of shares |
| | | |
|
| |
| 33.
Further information from a party to an agreement under Section 317 (Please see Notes for further information required): |
| Names of other parties | Address | Number of shares |
| | |
| Total number of shares in which a director is interested under sections 317 and 318 | |
|
| |
| 34.
Supplementary information: |
The percentage level of interest in the shares has reduced from 10.9177 to 10.8971 because of the increase in the number of issued shares due to the exercise of options and issue of 1,210,000 new shares on September 28, 2021 pursuant to Employee Stock Option Plan adopted by Ocumension Therapeutics on May 23, 2018.
|
| 35.
Log/Serial Number of the previous form: |
|
| 36.
Number of concert party document(s) under section 317 attached/uploaded: |
0
|
|
Date of filing this Form 3A: |
30/09/2021
(dd/mm/yyyy)
|
| |